Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 60%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 40%High 0 · 0%

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Quality of life at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

Quality of life at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

Quality of life at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: bevacizumab vs ranibizumab

No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.96 [0.9, 1.04]
1 study · 548 participants
Moderate

Anti‐VEGF vs control

Vision‐related quality of life · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
MD 6.69 [3.38, 9.99]
2 studies · 1134 participants
Moderate